Full Text View
Tabular View
No Study Results Posted
Related Studies
Fatty Acids During Pregnancy and Lactation and Body Fat Mass in Newborns
This study is currently recruiting participants.
Study NCT00362089   Information provided by Technische Universität München
First Received: August 8, 2006   Last Updated: January 11, 2007   History of Changes

August 8, 2006
January 11, 2007
June 2006
 
body fat mass of newborns
Same as current
Complete list of historical versions of study NCT00362089 on ClinicalTrials.gov Archive Site
  • body weight of newborns
  • body height of newborns
  • head circumference of newborns
  • blood lipids of pregnant and lactating women
  • fatty acid profile of plasma phospholipids and erythrocyte membrane lipids
  • daily intake of maternal fatty acids
Same as current
 
Fatty Acids During Pregnancy and Lactation and Body Fat Mass in Newborns
The Impact of the Nutritional Fatty Acids During Pregnancy and Lactation for Early Human Adipose Tissue Development

Pregnant and lactating women receive n-3 fatty acids starting from week 15 of gestation until 4 months post-partum (pp) in comparison to a control group, who only gets information about adequately healthy nutrition during pregnancy and lactation.

The amount of fat in newborns is measured through skinfold thickness, ultrasound, and magnetic resonance imaging (MRI).

It is hypothesised that a reduction in arachidonic acid intake and an increase of n-3 LC PUFAs (long chain polyunsaturated fatty acids) via supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) could lead to less expansive fat tissue development in the first year of life.

The prevalence of overweight and obese children and adolescents dramatically increased during the last two decades. In Germany every 5th school child is overweight and 4 - 8% of all children are obese.

Recent studies suggest that fatty acids in maternal nutrition may have an impact on the fat tissue development during the fetal period.

Animal studies showed that a reduction in the arachidonic acid intake, a higher intake of n-3 LC PUFAs (i.e. DHA and EPA) and a resulting lower n-6/n-3 fatty acid ratio in food will cause less expansive fat tissue development in the first year of life.

In vitro studies and personal observations in animal studies also showed that n-6 fatty acids (i.e. arachidonic acid) stimulate the differentiation of preadipocytes to adipocytes whereas n-3 fatty acids (i.e. DHA and EPA) have the contrary effect.

The impact of the maternal fatty acid pattern on the early fat tissue development can only be clarified in an intervention study.

Therefore it is planned to recruit 204 pregnant women in the 14th week of gestation. They will be randomly assigned to the intervention or control group.

The intervention group will receive n-3 LC-PUFAs (DHA and EPA) as fish oil capsules from the 15th week of gestation until 4 months pp, the control group will get nutrition counselling according to the recommendations of the German Society for Nutrition during the same time period. Blood samples of the pregnant and lactating women, umbilical cord blood, placental tissue and blood of the newborns will be collected for fatty acid analysis.

Body fat mass in newborns will be determined from delivery until 4 months pp via skinfold measurement, ultrasound, and MRI.

The hypothesis is that newborns in the group of the "supplemented" mothers will have less expansive fat tissue development than children from mothers in the control group.

This would be an innovative primary preventive approach in a period of increasing prevalence of overweight and obese children and adolescents.

 
Interventional
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
  • Overweight
  • Obesity
Procedure: Marinol D-40 starting from 15 wk gestation until 4 mo pp
 
Hauner H, Vollhardt C, Schneider KT, Zimmermann A, Schuster T, Amann-Gassner U. The impact of nutritional fatty acids during pregnancy and lactation on early human adipose tissue development. Rationale and design of the INFAT study. Ann Nutr Metab. 2009;54(2):97-103. Epub 2009 Mar 19.

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
204
August 2009
 

Inclusion Criteria:

  • Gestational age <= 15th week of gestation
  • Age: 18-43 years
  • Written informed consent
  • Body mass index (BMI) before pregnancy between 18 and 30 km/m2

Exclusion Criteria:

  • High risk pregnancy
  • Hypertonus
  • Chronic diseases (i.e. diabetes mellitus)
  • Psychiatric diseases
  • Former supplementation with LC-PUFA
Female
18 Years to 43 Years
Yes
Contact: Hans Hauner, Prof. +49 89 4140 ext 6770 hans.hauner@lrz.tu-muenchen.de
Contact: Ulrike Amann-Gassner, PhD +49 89 4140 ext 6782 ulrike.amann-gassner@wzw.tum.de
Germany
 
NCT00362089
 
EKFZ001_CN, INFAT
Technische Universität München
  • Else Kröner Fresenius Foundation
  • Unilever-Stiftung
  • Milupa GmbH
Principal Investigator: Hans Hauner, Prof. Else Kröner-Fresenius-Zentrum für Ernährungsmedizin, Technische Universität München
Technische Universität München
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP